154 related articles for article (PubMed ID: 38233537)
21. Concomitant Inhibition of PI3Kβ and BRAF or MEK in PTEN-Deficient/BRAF-Mutant Melanoma Treatment: Preclinical Assessment of SAR260301 Oral PI3Kβ-Selective Inhibitor.
Bonnevaux H; Lemaitre O; Vincent L; Levit MN; Windenberger F; Halley F; Delorme C; Lengauer C; Garcia-Echeverria C; Virone-Oddos A
Mol Cancer Ther; 2016 Jul; 15(7):1460-71. PubMed ID: 27196754
[TBL] [Abstract][Full Text] [Related]
22. Sensitivity to the MEK inhibitor E6201 in melanoma cells is associated with mutant BRAF and wildtype PTEN status.
Byron SA; Loch DC; Wellens CL; Wortmann A; Wu J; Wang J; Nomoto K; Pollock PM
Mol Cancer; 2012 Oct; 11():75. PubMed ID: 23039341
[TBL] [Abstract][Full Text] [Related]
23. Prenylation inhibition-induced cell death in melanoma: reduced sensitivity in BRAF mutant/PTEN wild-type melanoma cells.
Garay T; Kenessey I; Molnár E; Juhász É; Réti A; László V; Rózsás A; Dobos J; Döme B; Berger W; Klepetko W; Tóvári J; Tímár J; Hegedűs B
PLoS One; 2015; 10(2):e0117021. PubMed ID: 25646931
[TBL] [Abstract][Full Text] [Related]
24. Dual suppression of the cyclin-dependent kinase inhibitors CDKN2C and CDKN1A in human melanoma.
Jalili A; Wagner C; Pashenkov M; Pathria G; Mertz KD; Widlund HR; Lupien M; Brunet JP; Golub TR; Stingl G; Fisher DE; Ramaswamy S; Wagner SN
J Natl Cancer Inst; 2012 Nov; 104(21):1673-9. PubMed ID: 22997239
[TBL] [Abstract][Full Text] [Related]
25. Targeting Notch enhances the efficacy of ERK inhibitors in BRAF-V600E melanoma.
Krepler C; Xiao M; Samanta M; Vultur A; Chen HY; Brafford P; Reyes-Uribe PI; Halloran M; Chen T; He X; Hristova D; Liu Q; Samatar AA; Davies MA; Nathanson KL; Fukunaga-Kalabis M; Herlyn M; Villanueva J
Oncotarget; 2016 Nov; 7(44):71211-71222. PubMed ID: 27655717
[TBL] [Abstract][Full Text] [Related]
26. β-catenin signaling controls metastasis in Braf-activated Pten-deficient melanomas.
Damsky WE; Curley DP; Santhanakrishnan M; Rosenbaum LE; Platt JT; Gould Rothberg BE; Taketo MM; Dankort D; Rimm DL; McMahon M; Bosenberg M
Cancer Cell; 2011 Dec; 20(6):741-54. PubMed ID: 22172720
[TBL] [Abstract][Full Text] [Related]
27. Basal and treatment-induced activation of AKT mediates resistance to cell death by AZD6244 (ARRY-142886) in Braf-mutant human cutaneous melanoma cells.
Gopal YN; Deng W; Woodman SE; Komurov K; Ram P; Smith PD; Davies MA
Cancer Res; 2010 Nov; 70(21):8736-47. PubMed ID: 20959481
[TBL] [Abstract][Full Text] [Related]
28. The Small GTPase ARF6 Activates PI3K in Melanoma to Induce a Prometastatic State.
Yoo JH; Brady SW; Acosta-Alvarez L; Rogers A; Peng J; Sorensen LK; Wolff RK; Mleynek T; Shin D; Rich CP; Kircher DA; Bild A; Odelberg SJ; Li DY; Holmen SL; Grossmann AH
Cancer Res; 2019 Jun; 79(11):2892-2908. PubMed ID: 31048499
[TBL] [Abstract][Full Text] [Related]
29. Distinct MAPK and PI3K pathway mutations in different melanoma types in Taiwanese individuals.
Gao HW; Tsai WC; Perng CL; Wang WM; Chiang CP
Eur J Dermatol; 2018 Aug; 28(4):509-518. PubMed ID: 30325319
[TBL] [Abstract][Full Text] [Related]
30. Maximizing the Efficacy of MAPK-Targeted Treatment in PTENLOF/BRAFMUT Melanoma through PI3K and IGF1R Inhibition.
Herkert B; Kauffmann A; Mollé S; Schnell C; Ferrat T; Voshol H; Juengert J; Erasimus H; Marszalek G; Kazic-Legueux M; Billy E; Ruddy D; Stump M; Guthy D; Ristov M; Calkins K; Maira SM; Sellers WR; Hofmann F; Hall MN; Brachmann SM
Cancer Res; 2016 Jan; 76(2):390-402. PubMed ID: 26577700
[TBL] [Abstract][Full Text] [Related]
31. PTEN loss confers BRAF inhibitor resistance to melanoma cells through the suppression of BIM expression.
Paraiso KH; Xiang Y; Rebecca VW; Abel EV; Chen YA; Munko AC; Wood E; Fedorenko IV; Sondak VK; Anderson AR; Ribas A; Palma MD; Nathanson KL; Koomen JM; Messina JL; Smalley KS
Cancer Res; 2011 Apr; 71(7):2750-60. PubMed ID: 21317224
[TBL] [Abstract][Full Text] [Related]
32. Oncogenic BRAF(V600E) inhibits BIM expression to promote melanoma cell survival.
Cartlidge RA; Thomas GR; Cagnol S; Jong KA; Molton SA; Finch AJ; McMahon M
Pigment Cell Melanoma Res; 2008 Oct; 21(5):534-44. PubMed ID: 18715233
[TBL] [Abstract][Full Text] [Related]
33. Activated MEK cooperates with Cdkn2a and Pten loss to promote the development and maintenance of melanoma.
Yang H; Kircher DA; Kim KH; Grossmann AH; VanBrocklin MW; Holmen SL; Robinson JP
Oncogene; 2017 Jul; 36(27):3842-3851. PubMed ID: 28263969
[TBL] [Abstract][Full Text] [Related]
34. The Dietary Supplement Chondroitin-4-Sulfate Exhibits Oncogene-Specific Pro-tumor Effects on BRAF V600E Melanoma Cells.
Lin R; Xia S; Shan C; Chen D; Liu Y; Gao X; Wang M; Kang HB; Pan Y; Liu S; Chung YR; Abdel-Wahab O; Merghoub T; Rossi M; Kudchadkar RR; Lawson DH; Khuri FR; Lonial S; Chen J
Mol Cell; 2018 Mar; 69(6):923-937.e8. PubMed ID: 29547721
[TBL] [Abstract][Full Text] [Related]
35. BRN2 is a non-canonical melanoma tumor-suppressor.
Hamm M; Sohier P; Petit V; Raymond JH; Delmas V; Le Coz M; Gesbert F; Kenny C; Aktary Z; Pouteaux M; Rambow F; Sarasin A; Charoenchon N; Bellacosa A; Sanchez-Del-Campo L; Mosteo L; Lauss M; Meijer D; Steingrimsson E; Jönsson GB; Cornell RA; Davidson I; Goding CR; Larue L
Nat Commun; 2021 Jun; 12(1):3707. PubMed ID: 34140478
[TBL] [Abstract][Full Text] [Related]
36. Genome-wide screening identifies novel genes implicated in cellular sensitivity to BRAF
Ko T; Sharma R; Li S
Oncogene; 2020 Jan; 39(4):723-738. PubMed ID: 31548614
[TBL] [Abstract][Full Text] [Related]
37. In vivo identification of tumor- suppressive PTEN ceRNAs in an oncogenic BRAF-induced mouse model of melanoma.
Karreth FA; Tay Y; Perna D; Ala U; Tan SM; Rust AG; DeNicola G; Webster KA; Weiss D; Perez-Mancera PA; Krauthammer M; Halaban R; Provero P; Adams DJ; Tuveson DA; Pandolfi PP
Cell; 2011 Oct; 147(2):382-95. PubMed ID: 22000016
[TBL] [Abstract][Full Text] [Related]
38. Activating BRAF and PIK3CA mutations cooperate to promote anaplastic thyroid carcinogenesis.
Charles RP; Silva J; Iezza G; Phillips WA; McMahon M
Mol Cancer Res; 2014 Jul; 12(7):979-86. PubMed ID: 24770869
[TBL] [Abstract][Full Text] [Related]
39. Uncoupling of the LKB1-AMPKalpha energy sensor pathway by growth factors and oncogenic BRAF.
Esteve-Puig R; Canals F; Colomé N; Merlino G; Recio JA
PLoS One; 2009; 4(3):e4771. PubMed ID: 19274086
[TBL] [Abstract][Full Text] [Related]
40. Melanocytic nevus-like hyperplasia and melanoma in transgenic BRAFV600E mice.
Goel VK; Ibrahim N; Jiang G; Singhal M; Fee S; Flotte T; Westmoreland S; Haluska FS; Hinds PW; Haluska FG
Oncogene; 2009 Jun; 28(23):2289-98. PubMed ID: 19398955
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
